双成药业 (002693.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

57.0x

Market Cap

CNY 3.69B

MomentumView details →

1D Return

−5.42%

YTD Return

+25.72%

RSI (14)

42.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

57.0x

Market Cap

CNY 3.69B

RSI (14)

42.0

MomentumView details →

1D Return

−5.42%

YTD Return

+25.72%

ProfitabilityView details →

Gross Margin

56.68%

Net Margin

11.28%

EBITDA Margin

22.17%

ROE (TTM)

7.82%

ROA (TTM)

3.99%

Asset Turnover

0.35x

GrowthView details →

Revenue YoY

+71.62%

EPS YoY

+143.18%

FCF YoY

+163.03%

Revenue CAGR 3Y

+0.24%

EPS CAGR 3Y

+35.72%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

0.66x

Quick Ratio

0.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

+12.50%

Financials snapshotView financials →

Revenue (TTM)

288.53M

Net Income (TTM)

32.53M

Op. CF (TTM)

85.98M

Latest newsMore news →

Shuangcheng Pharmaceutical announced its first-half 2026 results: revenue of 117 million yuan, up 39.27% year-on-year; net profit attributable to shareholders of 13.63 million yuan, versus a net loss of 18.47 million yuan a year earlier; non-recurring-adjusted net profit of 10.90 million yuan, versus a loss of 21.02 million yuan a year earlier. The company declared no cash dividend, no bonus shares, and no capital reserve conversion.15d ago

Shuangcheng Pharmaceutical's deputy general manager Yao Zhong reduced his shareholding in the company by 40,500 shares through centralized bidding on August 4, 2026, accounting for 0.01% of total share capital, at an average price of 9.65 yuan per share, completing the reduction plan.30d ago

Similar companies

欧圣电气301187.SZ 易天股份300812.SZ 天沃科技002564.SZ 南矿集团001360.SZ 智动力300686.SZ 迈普医学301033.SZ Find similar companies →

Latest newsMore news →

Shuangcheng Pharmaceutical announced its first-half 2026 results: revenue of 117 million yuan, up 39.27% year-on-year; net profit attributable to shareholders of 13.63 million yuan, versus a net loss of 18.47 million yuan a year earlier; non-recurring-adjusted net profit of 10.90 million yuan, versus a loss of 21.02 million yuan a year earlier. The company declared no cash dividend, no bonus shares, and no capital reserve conversion.15d ago Shuangcheng Pharmaceutical's deputy general manager Yao Zhong reduced his shareholding in the company by 40,500 shares through centralized bidding on August 4, 2026, accounting for 0.01% of total share capital, at an average price of 9.65 yuan per share, completing the reduction plan.30d ago